RMD.AX - ResMed Inc.

ASX - ASX Delayed Price. Currency in AUD
-0.15 (-0.85%)
As of 2:49PM AEST. Market open.
Stock chart is not supported by your current browser
Previous Close17.59
Bid17.42 x 0
Ask17.44 x 0
Day's Range17.31 - 17.53
52 Week Range12.65 - 17.94
Avg. Volume1,003,948
Market Cap24.959B
Beta (3Y Monthly)0.75
PE Ratio (TTM)56.46
EPS (TTM)0.31
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2018-05-09
1y Target Est12.43
  • GlobeNewswire16 hours ago

    MatrixCare Appoints Geriatrician Dheeraj Mahajan as Chief Medical Officer, Executive Vice President

    MatrixCare announced today that Dheeraj Mahajan, MD, MBA, MPH, FACP, CMD, CIC, CHCQM, has joined its team as chief medical officer and executive vice president to advance MatrixCare’s vision of creating a seamless continuum where data moves with the patient, connecting both acute and post-acute care providers. Dr. Mahajan joins MatrixCare with more than 15 years as a practicing physician and is a nationally recognized expert and speaker on physician payment models, clinical documentation improvement, denial management, quality measurement in post-acute and long-term care, and transitional care quality improvement.

  • Business Wire2 days ago

    ResMed Inc. Completes $500M Private Placement Debt Offering

    ResMed Inc. (NYSE: RMD, ASX: RMD) announced today the successful pricing and closing of a private placement offering of $250,000,000 principal amount 3.24% senior notes due July 10, 2026, and $250,000,000 principal amount 3.45% senior notes due July 10, 2029. Net proceeds from the offering will be approximately $498 million, after deducting estimated fees and expenses related to the offering. The net proceeds will be used to pay down current borrowings on ResMed’s senior unsecured revolving credit facility.

  • GlobeNewswire2 days ago

    Evolus Expands Board of Directors with Appointment of Independent Directors Peter Farrell, Ph.D. and Karah Parschauer, J.D.

    NEWPORT BEACH, Calif., July 15, 2019 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.

  • Business Wire8 days ago

    The Lancet Publishes: More Than 936 Million Have Obstructive Sleep Apnea Worldwide

    More than 936 million people have obstructive sleep apnea – the disease’s first prevalence update in more than a decade – according to The Lancet Respiratory Medicine, the world’s leading journal in its field. The Lancet today published a multinational analysis by ResMed (RMD) (RMD.AX) and 12 academic leaders in sleep research. This figure is nearly 10 times greater than the World Health Organization’s 2007 estimate of more than 100 million, renewing calls for physicians to step up their efforts to screen, diagnose, and prescribe treatment for those who unknowingly suffer.

  • GuruFocus.com8 days ago

    Resmed Inc (RMD) CEO Michael J. Farrell Sold $823,128 of Shares

    CEO of Resmed Inc (NYSE:RMD) Michael J. Farrell sold 6,651 shares of RMD on 07/08/2019 at an average price of $123.76 a share.

  • Business Wire14 days ago

    ResMed to Report Fourth Quarter Fiscal 2019 Earnings on July 25, 2019

    ResMed today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2019 on Thursday, July 25, 2019, after the New York Stock Exchange closes.

  • Here’s What Hedge Funds Think About ResMed Inc. (RMD)
    Insider Monkey29 days ago

    Here’s What Hedge Funds Think About ResMed Inc. (RMD)

    Is ResMed Inc. (NYSE:RMD) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after adjusting for known risk attributes. […]

  • TheStreet.comlast month

    ResMed Could Rally Another 25% From Here

    During Friday night's Lightning Round of Mad Money, Jim Cramer said this about ResMed Inc. In the daily bar chart of RMD, below, we can see a wide-swinging sideways market for this stock. The daily On-Balance-Volume (OBV) line has been steady from March, and is close to making a new high for the move up.

  • Business Wirelast month

    New Analysis Shows Sleep Apnea More Common in Americas than Previously Thought

    ResMed (RMD) (RMD.AX) revealed roughly 170 million people across North and South America have sleep apnea, according to a study it presented at the annual SLEEP meeting hosted by the American Academy of Sleep Medicine (AASM) and the Sleep Research Society.

  • Markitlast month

    See what the IHS Markit Score report has to say about ResMed Inc.

    ResMed Inc NYSE:RMDView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for RMD with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding RMD totaled $6.23 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Business Wire2 months ago

    ResMed Appoints New South Asia General Manager to Help Drive Increased Awareness and Treatment of Sleep Apnea, Other Respiratory Diseases

    ResMed, a world leader in connected health solutions for sleep apnea, lung disease, and other chronic diseases, today announced the appointment of Shubhi Khurana as general manager for India and South Asia.

  • Business Wire2 months ago

    ResMed Announces Participation in the 40th Annual Goldman Sachs Global Healthcare Conference

    ResMed today announced that Rob Douglas, president and chief operating officer, will participate in a fireside chat discussion at the 40th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11, 2019, beginning at approximately 10:00 a.m.

  • Business Wire2 months ago

    ResMed Announces Participation in the 39th Annual William Blair Growth Stock Conference

    ResMed today announced that Mick Farrell, chief executive officer, will present at the 39th Annual William Blair Growth Stock Conference on Thursday, June 6, 2019, beginning at approximately 8:40 a.m.

  • Business Wire2 months ago

    ResMed Study Finds CPAP Adherence Improved by Remote Monitoring, Self-Monitoring across 3 Countries

    .@ResMed study finds #CPAP adherence improved by remote monitoring, self-monitoring across 3 countries

  • Business Wire2 months ago

    Age, Gender, Disease Severity Impact Adherence to Long-Term PAP Therapy More Than Previously Thought

    Age, gender, and disease severity all impact long-term #CPAP adherence more than previously thought, according to a million-patient study shown at #ATS2019 #sleepapnea

  • Business Wire2 months ago

    ResMed Elects Jan De Witte to Its Board of Directors

    ResMed (NYSE: RMD, ASX: RMD), a leader in cloud-connected medical devices and out-of-hospital SaaS solutions, today announced it has elected experienced business executive Jan De Witte to its board of directors. Mr. De Witte was appointed during ResMed’s regularly scheduled board meeting on May 16, 2019, to fill a newly created directorship, effective immediately.

  • Business Wire2 months ago

    Brightree Announces Access to CommonWell Health Alliance Network for Home Health and Hospice Customers

    Brightree® today announced plans for its Home Health and Hospice customers to access more than 50,000 provider locations and health systems nationwide via the CommonWell Health Alliance, a nonprofit national trade association of health IT companies, and through CommonWell to Carequality, a national, consensus-built common interoperability framework. This represents an important step forward in bridging the gap between out-of-hospital care providers and the broader care ecosystem, solving for when providers lose visibility into their patients’ care when they enter a post-acute care setting.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of RMD earnings conference call or presentation 2-May-19 8:30pm GMT

    Q3 2019 Resmed Inc Earnings Call

  • ResMed's Revenue Growth Accelerates
    Motley Fool2 months ago

    ResMed's Revenue Growth Accelerates

    The medical-device maker continues to roll out new products and grab market share.

  • Resmed Inc (RMD) Q3 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Resmed Inc (RMD) Q3 2019 Earnings Call Transcript

    RMD earnings call for the period ending March 31, 2019.

  • Associated Press2 months ago

    ResMed: Fiscal 3Q Earnings Snapshot

    The San Diego-based company said it had net income of 73 cents per share. Earnings, adjusted for amortization costs and pretax expenses, came to 89 cents per share. The results exceeded Wall Street expectations. ...

  • Business Wire2 months ago

    ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2019

    SAN DIEGO-- -- Year-over-year revenue grows 12%, gross margin improves 100 basis points, operating profit up 15% MatrixCare contributes positively to revenue, gross margin, and profit ResMed well-positioned for the future Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com ResMed Inc. , a world-leading connected health company, today announced ...

  • Motley Fool3 months ago

    Did David Stick His Neck Out Too Far With This 5-Stock Sampler?

    It’s time for the one-year update on a set of stocks that David Gardner picked to commemorate April the giraffe giving birth live on YouTube.

  • Business Wire3 months ago

    ResMed to Report Third Quarter Fiscal 2019 Earnings on May 2, 2019

    ResMed today announced it plans to release financial and operational results for the third quarter of fiscal year 2019 on Thursday, May 2, 2019, after the New York Stock Exchange closes.